# STOCKHOLM 1.0
#=GF ID   Mesothelin
#=GF AC   PF06060.16
#=GF DE   Mesothelin
#=GF AU   Moxon SJ;0000-0003-4644-1816
#=GF SE   Pfam-B_8552 (release 9.0)
#=GF GA   25.80 25.80;
#=GF TC   25.80 25.80;
#=GF NC   25.60 25.70;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -Z 75585367 --cpu 4 -E 1000 HMM pfamseq
#=GF TP   Repeat
#=GF CL   CL0020
#=GF RN   [1]
#=GF RM   10733593
#=GF RT   Mesothelin is not required for normal mouse development or
#=GF RT   reproduction. 
#=GF RA   Bera TK, Pastan I; 
#=GF RL   Mol Cell Biol 2000;20:2902-2906.
#=GF RN   [2]
#=GF RM   10500211
#=GF RT   Soluble member(s) of the mesothelin/megakaryocyte potentiating
#=GF RT   factor family are detectable in sera from patients with ovarian
#=GF RT   carcinoma. 
#=GF RA   Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE,
#=GF RA   Hellstrom I; 
#=GF RL   Proc Natl Acad Sci U S A 1999;96:11531-11536.
#=GF RN   [3]
#=GF RM   32983962
#=GF RT   Insights Into the Role of Mesothelin as a Diagnostic and
#=GF RT   Therapeutic Target in Ovarian Carcinoma.
#=GF RA   Shen J, Sun X, Zhou J;
#=GF RL   Front Oncol. 2020;10:1263.
#=GF RN   [4]
#=GF RM   33938941
#=GF RT   Mesothelin is a novel cell surface disease marker and potential
#=GF RT   therapeutic target in acute myeloid leukemia.
#=GF RA   Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA,
#=GF RA   Gerbing RB, Correnti C, Loken MR, Broderson LE, Pardo L, Le QH,
#=GF RA   Tang T, Leonti AR, Smith JL, Chou CK, Xu M, Triche T, Kornblau
#=GF RA   SM, Kolb EA, Tarlock K, Meshinchi S;
#=GF RL   Blood Adv. 2021;5:2350-2361.
#=GF DR   INTERPRO; IPR010335;
#=GF DR   SO; 0001068; polypeptide_repeat;
#=GF CC   This family consists of several mammalian pre-pro-megakaryocyte
#=GF CC   potentiating factor precursor (MPF) or mesothelin proteins.
#=GF CC   Mesothelin is a glycosylphosphatidylinositol-linked glycoprotein
#=GF CC   highly expressed in mesothelial cells, mesotheliomas, and
#=GF CC   ovarian cancer [1,2], which participates in cell adhesion,
#=GF CC   tumour progression, metastasis, and drug resistance [3]. Due to
#=GF CC   its overexpression in various tumours, it constitutes a
#=GF CC   diagnostic an therapy target [3,4]. This protein is predicted
#=GF CC   have superhelical structures with ARM-type repeats.
#=GF SQ   4
#=GS MSLN_HUMAN/1-629     AC Q13421.2
#=GS H0WNG9_OTOGA/1-635   AC H0WNG9.1
#=GS H0UUP8_CAVPO/11-633  AC H0UUP8.2
#=GS MSLN_MOUSE/1-624     AC Q61468.1
MSLN_HUMAN/1-629                MALPTARPLLGSCGTPALG.SLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISSLSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSE..PPEDLDALPLDLLLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEADVRALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQAPRR...PLPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLSMQEALSGTPCLLGPGPVL.TVLALLLASTL
H0WNG9_OTOGA/1-635              MALLTALSPRRSCRTAPHC.SLLLLLLTLGWVQPLRTQAGESRQQAAPLDPVLANLSSFTSLSPDRLLGFTCADVSGLSPEHVKELAVAMGQKNATLQADQLRCLAHGLPTHLAPEDLDAFLPDLLLFLNPAEFSGPQACAHFFSHISKANVDVLPRRSPERQRLLPAALVCRGVQGSQVSEEDVLALGGLACDLPGCFVANSAAALLPRLAGCPGSLDQDQQEAVRAVLQGRGPPYGSPSKWSVSTLDTLQGLLPILDQDFIQDIPKGVMTAWLQRFYRNPSGPRPELTVVLPRLRRDTEKEACPPGREAHVVEEKLVFYSDRELEACVDGALLVAEIDHVNALPFTYQQLNIFKRKLDKIYPKGYPESLIQHLGYFFLTMTPEDIHKWNVTSLQVVKDLLRVSKGRDMDAQATRHLSGLLPQVAALIAQYVKGNGWLDKDSLDALATFHPTYLCFFSSRQLGSVPPSIIWVVRPHDLDTCNQTQMDILYAKAHLTFQNVSGAEYFVKIQPFLGGASTEDLRALSQQNVSMDMVTFKTLKKEAVVGLTVQEVQNLLGPHVVGLKAEQKNSPVWDWILRQRQDDLDAMGLGLQGGIPNGYQVLDRSHPAALSDGHHLLGSRPMLSTMLALLLALAL
H0UUP8_CAVPO/11-633             MAWSTARLPLKSCMILTHS.SLL.LLLNLGWVQALRDQTVMTQKAAILLNPVLANKSNLASLDPSFLCDFTCTEVSGMSIEHAQELAMAIKQKNITLRVDQLHCLARHLSKHLVPKNLNIFPVDMLPFFNPDLFTGPQACTQFFSGIAKANVDVLPRGAPERRQLLLAALACQGVQGSLVSEDNVQALGGLACDLPGHIIATSAAVVLPRLATCPGPLDQNQQEAARAALQGGGTPYGPPSRWSVSTLDALQSLLAVLDQSIIRTIPKGVTNAWLHHTSQEPSGRWPDLTTILVRLKRSTEEKVCPPGRKPQVVDEDLFFYDNWELEACVDGALLATQMDRVNAIPFTYQQLNIFKHKLDETYPQGYPESLILSLGHFFYFMNPEDIQKWNVTSLDTLKALLKVSKKPNMDTKE...........VTLIARYLQGSGQLDKDTLDALAGFHPTYLCALSPEQLGSVPDSLLWAARPQDLDSCSSKQLVVLYPKAHLAFQNVSKPEYLEKISPFLGGVSIEDLHALSHQNVSMDMSTFKKLPVKVVERLTVAEVQNLLGPHMAGLKAEERNSPVKEWIFQQRQEDLDMLGLGLRGGIPNGYMILDFNSREAFSRGTLLLASGFLLALILVLLVAGTL
MSLN_MOUSE/1-624                MALPTARPLLGSCGSPICSRSFLLLLLSLGWIPRLQTQTTKTSQEATLLHAV.NGAADFASLPTGLFLGLTCEEVSDLSMEQAKGLAMAVRQKNITLRGHQLRCLARRLPRHLTDEELNALPLDLLLFLNPAMFPGQQACAHFFSLISKANVDVLPRRSLERQRLLMEALKCQGVYGFQVSEADVRALGGLACDLPGKFVARSSEVLLPWLAGCQGPLDQSQEKAVREVLRSGRTQYGPPSKWSVSTLDALQSLVAVLDESIVQSIPKDVKAEWLQHISRDPSRLGSKLTVIHPRFRRDAEQKACPPGKEPYKVDEDLIFYQNWELEACVDGTMLARQMDLVNEIPFTYEQLSIFKHKLDKTYPQGYPESLIQQLGHFFRYVSPEDIHQWNVTSPDTVKTLLKVSKGQKMNAQA...........IALVACYLRGGGQLDEDMVKALGDIPLSYLCDFSPQDLHSVPSSVMWLVGPQDLDKCSQRHLGLLYQKACSAFQNVSGLEYFEKIKTFLGGASVKDLRALSQHNVSMDIATFKRLQVDSLVGLSVAEVQKLLGPNIVDLKTEEDKSPVRDWLFRQHQKDLDRLGLGLQGGIPNGYLVLDFNVREAFSSRASLLGPGFVLIWIPALLPALRL
#=GC seq_cons                   MALsTARs.LtSCtosspu.SLLhLLLoLGWVQsLRTQsscTpQpAs.LcsVLANhushuSLsPshLLGFTCsEVSGLShE+s+ELAhAltQKNlTLps-QLRCLA++LscHLsPE-LsAhPlDLLLFLNPshFoGPQACs+FFStIoKANVDVLPRtuPERQRLL.AALsCpGVpGS.VSEsDVpALGGLACDLPG+FVApSAtVLLPRLAuCPGPLDQsQQEAsRAsLQGGGsPYGPPS+WSVSTLDALQuLLsVLDQsIIpoIPKGVhsAWLQ+hSR-PSthtP-LTllhPRhRR-sEccACPPG+csphVDEcLlFYpsWELEACVDGALLAsQMD+VNAIPFTYpQLsIFKHKLDchYPQGYPESLIQpLGaFFhhMoPEDI+KWNVTSL-TlKsLL+VSKGpcMssQA...........ssLIApYl+GsGQLDKDoLDALusFaPoYLCshSPcpLuSVPsSllWsVRPQDLDoCsp+QLslLYsKA+LAFQNVSGsEYF.KIpsFLGGASsEDL+ALSQQNVSMDhuTFK+Lps-uVlsLTVAEVQpLLGPHlsGLKAEE+pSPV+DWIhRQRQ-DLDtLGLGLQGGIPNGYhVLDhshpEAhSssspLLGsG.lL.hlLALLlAhsL
